BioNTech acquires CureVac for $1.25 billion

BioNTech announced its acquisition of CureVac for approximately $1.25 billion in June 2025. The acquisition integrates CureVac's mRNA platform and clinical-stage oncology programs, strengthening BioNTech's cancer vaccine capabilities and expanding its pipeline.